Bowave Pharmaceuticals Secures Tens of Millions of RMB in Angel Funding from Xingze Capital to Advance RNAi Therapeutics Platform

Investment Circle (ID: pedaily2012), April 27 news: Shanghai Argo Biopharma Co., Ltd. (“Argo Biopharma”) recently announced the completion of a tens-of-millions-of-yuan angel financing round, exclusively led by Apricot Capital. The funds raised will be used for the development of the company’s RNA interference (RNAi) product pipeline and the establishment of a novel RNAi technology platform.

RNA interference (RNAi) is one of the most significant technological breakthroughs in the biopharmaceutical field over the past two decades. This discovery was awarded the Nobel Prize in 2006. Theoretically, RNAi can silence disease-related genes through sequence-specific binding at the RNA level, thereby overcoming the target limitations associated with traditional large and small molecules. With the recent maturation of delivery and modification technologies, the druggability of RNAi therapeutics has been significantly enhanced, paving the way for explosive growth across the industry.

Currently, there are only a handful of companies in China engaged in the research and development of RNAi therapeutics. Argo Biopharma was founded by several scientists who returned to China with extensive experience in the in-depth development of RNAi drugs. The team possesses rich expertise across the entire RNAi drug development process, including bioinformatics and nucleic acid sequence design, chemical modification, GalNAc conjugation technology, extrahepatic delivery technology development, and CMC for oligonucleotides. Leveraging next-generation drug design, the company’s team will...Procedure, development strategy to expand the indications for RNAi therapy development, filling the domestic gap in this field.

Apricot CapitalPartnerChen HaiGang stated, “As a new generation of pharmaceutical technology, RNAi drugs have broken the shackles of traditional drug development and hold immense potential for growth. Apricot Capital is highly optimistic about Argo’s team’s accumulation of core technologies in RNA therapeutics and their experience in industrialization. We believe that, leveraging its next-generation RNAi drug development platform, the company is poised to become an industry leader.”

About Argo Biopharma

Argo Biopharma, established in 2021, is dedicated to the development of next-generation RNAi therapeutics. Currently registered and based in Jiading District, Shanghai, the Company will leverage its world-leading drug design and development platform to provide better treatment options for patients worldwide.

About Apricot Capital

Apricot Capital, established in 2015, derives its name from the aspiration to integrate resources within the broader healthcare industry through capital investment, thereby promoting industry development and benefiting humanity. The firm currently manages assets totaling nearly RMB 4 billion. Its investment team comprises more than 20 professionals and advisors with extensive experience in healthcare investments worldwide, boasting diverse expertise in life sciences, pharmaceuticals, finance, and law. Since its inception, Apricot Capital has focused on investing in outstanding early-stage and growth-stage enterprises in the healthcare sector, with a portfolio spanning biopharmaceuticals and medical devices, among other areas. Investee companies include numerous star enterprises such as Junshi Biosciences (01877.HK), Akeso Biopharma (09926.HK), China Antibody (03681.HK), HeartCare Medical (02160.HK), Sinovation Pharmaceuticals, Liuhe Ningyuan, and Innovent Micro. Apricot Capital remains committed to fostering innovation and growth among Chinese enterprises and advancing societal industrial progress. Leveraging its team’s rich industry experience, global resource network, and outstanding reputation in the field, the firm spares no effort...Yu Lito effectively help entrepreneurs realize their entrepreneurial dreams.